未登录

L

Lihuang Su

Wenzhou Medical University

H指数:9

被引数:238

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unveiling Novel Macrophage-Specific Biomarkers in MASH through Single-Cell Sequencing for Diagnostic Modeling

通过单细胞测序在MASH中揭示新型巨噬细胞特异性生物标志物以用于诊断模型构建

Journal of Lipid Research

IF4.1

2026-04-280

OAAI

Bile Acids as a Liver-Muscle Axis Mediator: Moving From Association to Intervention

胆汁酸作为肝-肌轴介导因子：从关联到干预

Liver International

IF5.2

2026-04-200

PRE

Exploring the Causal Relationship Between Gut Microbiota and Pulmonary Artery Hypertension: Insights From Mendelian Randomization

探索肠道菌群与肺动脉高压之间的因果关系: 来自孟德尔随机化的见解

JOURNAL OF THE AMERICAN HEART ASSOCIATION

IF5.3

2025-03-180

OAAI

Hypoxia-Induced and Glucuronic Acid-Modified Extracellular Vesicles from Mesenchymal Stromal Cells Treat Pulmonary Arterial Hypertension by Improving Vascular Remodeling

IF9.1

2024-12-110

PRE

Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation

ACTA PHARMACOLOGICA SINICA

IF8.4

2024-05-081

OAAI

Impact of gut microbiota on nonalcoholic fatty liver disease: insights from a leave-one-out cross-validation study

FRONTIERS IN MICROBIOLOGY

IF4.5

2024-01-084

OAAI

Progress and Perspective of CRISPR-Cas9 Technology in Translational Medicine

CRISPR-Cas9技术在转化医学中的应用进展与展望

ADVANCED SCIENCE

IF14.1

2023-06-257

OAAI

Maresin 1 intervention reverses experimental pulmonary arterial hypertension in mice

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2022-08-0920

OAAI

Downregulation of CPA4 inhibits non small-cell lung cancer growth by suppressing the AKT/c-MYC pathway

MOLECULAR CARCINOGENESIS

IF3.2

2019-08-0920

OAAI